News & Media

Displaying 1 - 20 of 48
October 10, 2018

UCSB, UCSD and SBP researchers trace the complex and variable pathways to the deadly condition known as sepsis

September 20, 2018

A new app developed by UCSB researchers enables a smartphone to ID bacteria in just one hour.

January 24, 2018

The Wille Family Foundation has made another generous donation to the Center for Nanomedicine, which supports the CNM’s research to discover and prevent the origins of common grievous diseases.

December 21, 2017

A startling discovery published today in the journal Science reveals how your past history of minor bacterial infections can add up with age to cause a severe inflammatory disease.

November 10, 2017

Peptide recognizes vasculature associated with brain inflammation

October 02, 2017

The Karl Meyer Award was established in 1990 to honor the distinguished career of Karl Meyer and his outstanding contributions to the field of Glycobiology. This international award is given to well-established scientists with currently active research programs who have made widely recognized major contributions to the field of Glycobiology.

June 06, 2017

When a patient is prescribed the wrong antibiotic to treat a bacterial infection, it’s not necessarily the physician who is at fault. The current antibiotic assay — standardized in 1961 by the World Health Organization and used worldwide — is potentially flawed.

February 08, 2017

For the fifth consecutive year, the Wille Family Foundation has provided a generous donation to support the Center for Nanomedicine.

July 19, 2016

UCSB scientists collaborate with multiple institutions to conduct biomedical research on
infectious disease and sepsis, thanks to a $12.8 million grant

By Julie Cohen

June 28, 2016

A new study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) describes a technology that could lead to new therapeutics for traumatic brain injuries. The discovery, published in Nature Communications, provides a means of homing drugs or nanoparticles to injured areas of the brain.

June 07, 2016

The Center for Nanomedicine enthusiastically welcomes two top-ranked research and clinical scientists as new members of our center.  Both will participate as inter-institutional adjunct professors.  Their expertise complements CNM biomedical research programs to identify the causes of disease at the nanoscale and molecular level needed to develop more effective diagnostics and therapeutics.

Photo Credit:  Lynda Harris, University of Manchester.     targeted drug deliver, placenta, tumor-homing peptides, research
May 10, 2016

UCSB scientists provide proof of principle for safe, targeted delivery of drugs to the placenta during pregnancy.

January 16, 2016

For the fourth consecutive year, the Wille Family Foundation has provided a generous donation to the Center for Nanomedicine.

November 25, 2015

Dr. Erkki Ruoslahti, CNM co-Founder and Distinguished Professor of UCSB and the SBP Medical Discovery Institute, and his colleagues have generated a breakthrough in targeting drugs to cancer.

October 19, 2015

Physiological processes in the body are in large part determined by the composition of secreted proteins found in the circulatory systems, including the blood. Each of the hundreds of proteins in the blood has a specific life span that determines its unique range of abundance. In fact, measurements of their quantities and activities contribute to many clinical diagnoses. However, the way in which normal protein concentrations in the blood are determined and maintained has been a mystery for decades.

August 20, 2015

Bacteria are pretty wily creatures. Take for example, an organism such as Salmonella, which succumbs to antibiotics in lab tests, but can become highly resistant in the body.
It is an example of what UC Santa Barbara biologist Michael Mahan refers to as the Trojan horse strategy. Identified through new research conducted by Mahan and his colleagues, the Trojan horse strategy may explain why antibiotics are ineffective in some patients despite lab tests that predict otherwise. The research findings appear in the journal EBioMedicine.

August 01, 2015

We are pleased to announce a new member of the CNM and our second inter-institutional adjunct professorial position.  Dr. Jeffrey W. Smith, a world expert in protein proteolysis in health and disease has joined the CNM effective August 1, 2015.  “We are delighted to have Jeff among our faculty, he is an exceptional biomedical researcher and a key collaborator in many of the ongoing CNM research projects at UCSB.”  Said Dr. Jamey Marth, director of the CNM.  Dr. Smith is a senior faculty member of the Sanford-Burnham Prebys (SBP) Medical Discovery Institute.  “I am pleased to join the CNM, it is an exceptional team of biomedical scientists working at the forefront of understanding and treating diseases that affect millions of humans.  Our collaborative work in sepsis research for example, is leading to new discoveries that are transforming our understanding of this deadly syndrome.  I am also excited to contribute to CNM projects on diabetes, inflammatory bowel diseases, and autoimmune diseases.  In addition, the magnificent research of Dr. Erkki Ruoslahti, co-founder of the CNM, is leading the way to new and more effective nanoparticle-based treatments of cancer.  The CNM represents a unique and successful combination of technologically inclined and biomedically relevant research, and is an unparalleled research institute at UCSB.” 

June 24, 2015

Our partner institute the Sanford-Burnham Medical Research Institute has received a gift of $100 million from prominent San Diego developer, philanthropist, and Sanford-Burnham honorary trustee Conrad Prebys.  This is the largest donation ever made by Prebys and will be used to further implement the Institute’s 10-year strategic vision to accelerate the delivery of innovative new treatments that will have a tangible impact on improving human health.  “A gift of this magnitude is significant in many ways,” said Sanford-Burnham Chief Executive Officer Perry Nisen, M.D., Ph.D.  “It enables us to conduct translational research to advance laboratory discoveries and clinic-ready drug candidates further along the development pipeline, progressing toward therapies, preventions, and cures for patients who desperately need them.  We are profoundly grateful to Conrad Prebys for this extraordinary gift.” 

In recognition of Prebys’ contribution, Sanford-Burnham Medical Research Institute will now bear his name, along with the other Institute namesakes T. Denny Sanford and Malin Burnham.  Effective June 24, the new name is now the Sanford Burnham Prebys Medical Discovery Institute.